Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Change in Receivables (2016 - 2020)

Plus Therapeutics (PSTV) has disclosed Change in Receivables for 11 consecutive years, with -$951000.0 as the latest value for Q3 2020.

  • On a quarterly basis, Change in Receivables fell 119.72% to -$951000.0 in Q3 2020 year-over-year; TTM through Jun 2021 was -$951000.0, a 199.37% decrease, with the full-year FY2020 number at -$1.2 million, down 197.17% from a year prior.
  • Change in Receivables was -$951000.0 for Q3 2020 at Plus Therapeutics, down from -$27000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $4.8 million in Q3 2019 to a low of -$3.6 million in Q4 2019.
  • A 5-year average of -$39105.3 and a median of -$138000.0 in 2017 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 11383.33% in 2019; the steepest drop was 2451.05% in 2019.
  • Plus Therapeutics' Change in Receivables stood at $270000.0 in 2016, then tumbled by 151.11% to -$138000.0 in 2017, then decreased by 3.62% to -$143000.0 in 2018, then tumbled by 2451.05% to -$3.6 million in 2019, then skyrocketed by 73.93% to -$951000.0 in 2020.
  • Per Business Quant, the three most recent readings for PSTV's Change in Receivables are -$951000.0 (Q3 2020), -$27000.0 (Q2 2020), and -$191000.0 (Q1 2020).